Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Yuxi Walvax Biotechnology Co., Ltd.

Home Clinical Trial Sponsors and OrganizationsYuxi Walvax Biotechnology Co., Ltd.

Yuxi Walvax Biotechnology Co., Ltd.

ACTIVE

No. 83, Dongfeng South Road, High-Tech Zone, 云南省昆明市, 云南省, Chinawww.walvax.comSubsidiary2,388 employeesEstablished: 2001-01-16

Also known as:

walvax biotechnology co., ltd.

Part of Yuxi Walvax Biotechnology Co., Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

8

2 active

Approvals

3

Total approvals

Agencies

1

Regulatory bodies

Founded

2001

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

4

50.0%

Phase 1

3

37.5%

Phase 4

1

12.5%

Trial Status Distribution

Active, not recruiting

1

12.5%

Completed

4

50.0%

Not yet recruiting

1

12.5%

Unknown

2

25.0%

Clinical Trials

Trials sponsored by this organization (8)

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13

Active, not recruiting

Nov 2023630 participants

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Not yet recruiting

Dec 2022120 participants

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

Jul 2022120 participants

A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

Jul 202128,000 participants

A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years

Dec 2020260 participants

Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

Jul 2018100 participants

Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)

Apr 20162,760 participants

Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children

Sep 20121,660 participants

Approvals

Approvals by Agency

PHILIPPINES

Philippines FDA

3

Approvals

Recent Approvals

09 January 2024

03 November 2023

03 November 2023

News

No news articles found

On this page

Overview
Clinical Trials8
Approvals3
News

Back to Organizations